Gestational Trophoblastic Disease (GTD)

Summary

Gestational trophoblastic disease (GTD) is a rare pregnancy-related tumour spectrum, from benign moles to malignant neoplasia (invasive mole, choriocarcinoma, PSTT, ETT). It presents with vaginal bleeding or persistent symptoms post-pregnancy, diagnosed by β-hCG, ultrasound, and histology, and managed with evacuation, chemotherapy, or surgery, with high cure rates.

Definition & Pathophysiology

Gestational trophoblastic disease (GTD) refers to a heterogeneous group of rare pregnancy-related tumours arising from abnormal proliferation of trophoblastic tissue. GTD encompasses both benign (pre-malignant) and malignant conditions, with a spectrum ranging from molar pregnancies to highly aggressive neoplasms.

Pathophysiologic Basis

GTD arises from abnormal fertilisation events leading to atypical chromosomal complements and dysregulated trophoblastic growth:

• Complete mole: Results from fertilisation of an "empty" (anucleate) ovum by a single sperm that duplicates or by two sperm. Paternal disomy yields a 46,XX (90%) or 46,XY (10%) karyotype with no embryonic tissue whatsoever. Microscopically, there is diffuse villous oedema (hydropic swelling) with circumferential trophoblastic proliferation, and risk of malignant transformation is 15–20%.
• Partial mole: Results from fertilisation of a normal ovum by two sperm, producing triploidy (69,XXY, 69,XXX, or 69,XYY). Characterized by focal villous oedema and variable embryonic development, with lower malignant risk (<5%).
• Neoplastic forms (invasive mole, choriocarcinoma, PSTT, ETT): Malignant transformation with myometrial invasion, vascular dissemination, and metastatic potential, driven by unrestricted trophoblastic proliferation and hCG production.

The excessive production of β-hCG in molar pregnancy is responsible for the most distinctive clinical features (hyperemesis, thyrotoxicosis, preeclampsia).

Classification: Pre-malignant vs. Malignant GTD

Pre-malignant GTD (Hydatidiform Mole)

Complete Molar Pregnancy

• Results from fertilisation of an "empty" ovum by a single sperm that duplicates (most common) or two sperm.
• Karyotype: 46,XX (90%) or 46,XY (10%), entirely paternal in origin.
• No fetus, amniotic fluid, or placenta develops.
• Risk of malignant transformation: 15–20%

Partial Molar Pregnancy

• Results from fertilisation of a normal ovum by two sperm.
• Karyotype: 69,XXY (70%), 69,XXX (27%), or 69,XYY (3%).
• May present with abnormal fetus/placenta (triploid or mosaic).
• Risk of malignant transformation: <5%

Malignant GTD (Gestational Trophoblastic Neoplasia, GTN)

Invasive Mole – Locally invasive form of molar pregnancy with myometrial infiltration, occasionally metastasising. Arises in approximately 10–15% of complete molar pregnancies.

Choriocarcinoma– Highly malignant tumour composed of cytotrophoblasts and syncytiotrophoblasts without chorionic villi. Frequently metastasises to lungs (80%), brain, liver, and vagina. May follow molar pregnancy or normal/ectopic pregnancy; rapid progression if untreated.

Placental Site Trophoblastic Tumour (PSTT) – Rare malignancy of intermediate trophoblasts, often arising after normal pregnancy or miscarriage. May present with persistent bleeding and a uterine mass; lower hCG elevation than other GTN forms.

Epithelioid Trophoblastic Tumour (ETT) – Rare variant resembling squamous carcinoma, arising from chorionic-type intermediate trophoblasts. Slow-growing with moderate malignant potential.

Clinical Features & Risk Factors

Clinical Features of Molar Pregnancy

Additional findings:

• Abdominal pain and uterine enlargement (soft, boggy consistency).
• Passage of vesicles ("grape-like" tissue).
• Theca lutein ovarian cysts (30–60% of cases), which regress post-evacuation.

Clinical Features of Gestational Trophoblastic Neoplasia (GTN)

Local disease:

• Persistent or heavy vaginal bleeding after pregnancy/miscarriage.
• Enlarged uterus or inadequate involution postpartum.

Metastatic features (site-specific):

• Lungs (most common): Cough, dyspnoea, haemoptysis; "cannonball metastases" on chest imaging.
• Brain: Seizures, headaches, focal neurologic deficits.
• Liver: Abdominal pain, hepatomegaly, jaundice.
• Vagina: Vaginal nodules (highly vascular, prone to bleeding).

Key Risk Factors for GTD

• Prior molar pregnancy (highest risk; ~1–2% chance of recurrence, not reduced by change of partner).
• Extremes of maternal age: <20 years or >35 years.
• History of miscarriage or infertility.
• Ethnic predisposition: Higher incidence in Asian and Indian populations.

Investigations & Diagnosis

Laboratory Investigations

Serum β-hCG (first-line): Markedly elevated; serial monitoring is the cornerstone of diagnosis and surveillance. In GTD, levels are typically much higher than expected for gestational age.

Urinary pregnancy tests: Persistently positive post-partum (abnormal) — a red flag for persistent GTD.

Pelvic Ultrasound

Complete mole: Echogenic "snowstorm" or "bunch of grapes" appearance with multiple cystic spaces, large placental mass, and no fetal parts.

Partial mole: Thickened, cystic placenta with possible fetal parts visible ("Swiss cheese" appearance); more irregular than complete mole.

Histopathology (Definitive Diagnosis)

Complete mole histology: Diffuse villous oedema, circumferential trophoblastic proliferation, absent or scant fetal tissue, and absence of vascular invasion.

p57 immunostaining (KIP2 — maternal imprinted gene):

• Negative in complete mole (no maternal DNA).
• Positive in partial mole (maternal DNA present).
• This is a critical ancillary test in challenging cases.

Imaging for Metastasis (if GTN Suspected)

Chest X-ray (first-line): Essential because lungs are the most common site of metastases. Look for "cannonball" nodules (large, round, well-demarcated opacities).

Choriocarcinoma histology and immunostaining:

CT/MRI and pelvic ultrasound: Used for assessing myometrial invasion, uterine mass, and organ metastases (brain, liver) when indicated by clinical presentation or elevated β-hCG post-treatment.

Management & Complications

Management of Molar Pregnancy

Surgical evacuation: Suction curettage is first-line for both complete and non-viable partial molar pregnancies. Avoid medical management (misoprostol) to reduce trophoblastic embolisation risk.

Anti-D immunoglobulin: Administer to all Rh-negative women post-evacuation (standard dose 500 IU per mL of fetal RBCs).

Serial β-hCG monitoring (mandatory): Weekly measurement until undetectable, followed by monthly monitoring for 6–12 months. This is critical for early detection of persistent GTD or malignant transformation.

Contraception during surveillance: Highly effective contraception is recommended during the entire monitoring period to avoid confusion between a new pregnancy and persistent GTD (which would elevate β-hCG further).

GTD referral centre registration: Recommended in many countries (UK, Australia) for standardised surveillance protocols and rapid access to chemotherapy if needed.

Management of Gestational Trophoblastic Neoplasia (GTN)

Chemotherapy (cornerstone of treatment):

• Low-risk disease: Single-agent methotrexate or actinomycin D.
• High-risk disease: Multi-agent chemotherapy (e.g., EMA/CO — etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine).

Surgery: Hysterectomy or excision of metastases considered in selected cases (e.g., isolated brain or liver lesions, or when chemotherapy fails).

Cure rates: >95% for good-prognosis GTN; ~65% for poor-prognosis metastatic disease (historically, now improving with multi-agent therapy).

Complications

Associated with molar pregnancy:

• Haemorrhage and anaemia (may require transfusion).
• Uterine perforation and infection during curettage.
• Thyrotoxicosis crisis (severe β-hCG-mediated thyrotoxicosis requiring beta-blockers and antithyroid drugs).
• Preeclampsia/eclampsia (can occur before 20 weeks, unusually early).
• Disseminated intravascular coagulation (rare but life-threatening).
• Pulmonary trophoblastic embolisation during evacuation.

Malignant transformation: Complete mole → 15–20% risk of GTN; partial mole → <5% risk.

Prognosis & Follow-up

Molar pregnancy: With early diagnosis and specialist care, most women achieve complete remission and retain full fertility. Risk of repeat molar pregnancy in a subsequent pregnancy is ~1–2%.

GTN: Most cases are curable with chemotherapy, even when metastatic. Patients who achieve remission can become pregnant again, though careful surveillance with β-hCG is essential in subsequent pregnancies.

Key Points for Exams – نقاط مهمة للامتحانات

Overview of Gestational Trophoblastic Disease

High-Yield Exam Pearls

• Molar pregnancy = β-hCG alarm: Levels are disproportionately high for dates. Serial monitoring is mandatory post-evacuation.
• The "VLHHP" mnemonic: Vaginal bleeding, Large uterus for dates, Hyperemesis, Hyperthyroidism, Preeclampsia (<20 weeks) are all driven by excessive β-hCG.
• Complete vs. Partial at a glance: Complete = no fetus, paternal DNA only, 15–20% malignant risk, p57 negative. Partial = abnormal fetus present, triploid (2n+n), <5% risk, p57 positive.
• Theca lutein cysts: Present in 30–60% of complete moles; regress spontaneously post-evacuation (no surgery needed).
• p57 immunostain: Maternal imprinted gene → negative in complete mole, positive in partial and normal pregnancy. Gold-standard ancillary test for borderline cases.
• Surveillance is non-negotiable: Weekly β-hCG until undetectable, then monthly for 6–12 months. Persistent elevation or rise = GTN (start chemotherapy).
• Choriocarcinoma metastases: Lungs (80%) → "cannonball" nodules; brain, liver, and vagina also common. Chest X-ray is essential screening.
• Cure rates are excellent: >95% for good-prognosis disease; ~65% for poor-prognosis metastatic disease. Fertility preserved in most remitted cases.
• Post-partum hemoptysis and dyspnea → suspect choriocarcinoma with cannonball lung metastases. Order β-hCG immediately — persistent elevation post-partum is the critical red flag for GTN.
• Contraception mandatory during surveillance: A new pregnancy would confound β-hCG interpretation and delay GTN diagnosis.
• Risk of recurrence: After one molar pregnancy, ~1–2% chance of another molar pregnancy in the next gestation (not >50%).